Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Operating Leases (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Operating Leases readings, the most recent being $117000.0 for Q4 2024.

  • On a quarterly basis, Operating Leases fell 74.89% to $117000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $117000.0, a 74.89% decrease, with the full-year FY2024 number at $117000.0, down 74.89% from a year prior.
  • Operating Leases hit $117000.0 in Q4 2024 for Unicycive Therapeutics, down from $265000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $800000.0 in Q4 2022 to a low of $29000.0 in Q3 2022.
  • Median Operating Leases over the past 4 years was $274000.0 (2024), compared with a mean of $351153.8.
  • Biggest five-year swings in Operating Leases: soared 1803.45% in 2023 and later crashed 74.89% in 2024.
  • Unicycive Therapeutics' Operating Leases stood at $155000.0 in 2021, then skyrocketed by 416.13% to $800000.0 in 2022, then crashed by 41.75% to $466000.0 in 2023, then crashed by 74.89% to $117000.0 in 2024.
  • The last three reported values for Operating Leases were $117000.0 (Q4 2024), $265000.0 (Q3 2024), and $274000.0 (Q2 2024) per Business Quant data.